RecipientAmount (million)Deal/Technology HighlightLead InvestorsDeal TypeCountry
BTG plc.$4,200 BTG has three key businesses, the largest of which is its Interventional Medicine portfolio which encompasses several peripheral interventional product lines. The interventional oncology franchise includes the TheraSphere® Y-90 radiotherapy microspheres and the GALIL™ cryoablation system, used to treat patients with liver, kidney and other cancers.Boston ScientificAcquisitionUnited Kingdom
AstraZeneca$1,500 AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus. Sobi will also have the right to participate in AstraZeneca’s share of US profits and losses related to potential new medicine MEDI8897. AstraZeneca will continue to develop MEDI8897 in collaboration with Sanofi Pasteur, the vaccines division of Sanofi S.A.Swedish Orphan Biovitrum ABDivestmentUnited Kingdom
Pacific Biosciences$1,200 While Illumina’s accurate and economic short-read sequencing platforms address the majority of sequencing applications optimally, select applications, such as de novo sequencing and sequencing of highly homologous regions of genomes, are better addressed with accurate long-reads. Illumina AcquisitionUnited States
Arena Pharmaceuticals$800 This transaction represents a significant milestone in the development of ralinepag and will strategically position Arena to aggressively advance our best-in-class pipeline, anchored by etrasimod and olorinab, with the focus and resources essential for long-term success."United TherapeuticsLicensing AgreementUnited States
MatrixCare$750 MatrixCare will continue to operate as a standalone business within ResMed’s SaaS portfolio, with targeted commercial, technical and operating links to ResMed and Brightree. There will be no immediate changes to management, locations or business processes. MatrixCare CEO John Damgaard will continue in his current role, reporting to Raj Sodhi.ResMedAcquisitionUnited States
Perceptive Credit Opportunities Fund II (Perceptive Advisors)$675 Fund II exceeded its target and was oversubscribed, reaching its hard cap. With the closing of Fund II, Perceptive manages approximately $1 billion of capital dedicated to private credit. Perceptive Credit Opportunities will continue its focused investment strategy in Fund II, which centers on providing customized, minimally-dilutive debt financing solutions to innovative healthcare companies.UndisclosedInvestmentUnited States
iNtRON Biotechnology$668 Roivant has created a dedicated subsidiary to pursue the global development and commercialization of endolysin products from iNtRON Bio. Roivant plans to initiate a Phase 2 trial for SAL200 in 2019.Roivant SciencesLicensing AgreementSouth Korea
Sarepta Therapeutics$500 Sarepta intends to use the net proceeds from the offering principally for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or acquisition of complementary products and technologies and other general corporate purposes.UndisclosedIPOUnited States
AstraZeneca$350 The rights cover markets outside the US and the US royalties for the medicines. Covis Pharma currently commercialises Alvesco, Omnaris and Zetonna in the US and will become the owner of the medicines upon closing.Covis Pharma B.V.DivestmentUnited Kingdom
Biomatics Capital Partners$300 The announcement comes after Biomatics successfully completed its first fund, which invested $200 million into more than a dozen companies including GRAIL, Denali Therapeutics, Verana Health, Aledade, eGenesis, BlackThorn Therapeutics and Omniome. UndisclosedInvestmentUnited States
Genomics Medicine Ireland (GMI)$295 The GMI acquisition forms part of a $400 million investment programme in precision medicine unveiled in Dublin today by WuXi NextCODE and a consortium of Irish and international sovereign and technology investors, and which positions Ireland to play a leading role in the global innovation of genome-driven drug discovery and diagnostics.WuXi NextCODEAcquisitionIreland
Leerink Holdings$280 The new entity, SVB Leerink, will operate as a wholly-owned subsidiary of SVB Financial Group. With the acquisition, SVB will complement its commercial banking and lending products with a full range of investment banking services focused on healthcare and life science companies. SVB Financial GroupAcquisitionUnited States
ACADIA Pharmaceuticals$275 ACADIA has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA has ongoing clinical development efforts in dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome.UndisclosedIPOUnited States
Avista Pharma Solutions$252 Cambrex will enter the large and growing market for early stage small molecule development and testing services. Avista offers a broad suite of scientifically differentiated services ranging from API and drug product development and cGMP manufacturing to stand-alone analytical, microbiology testing and solid state sciences.Cambrex CorporationAcquisitionUnited States
Huadong Medicine Company Limited (HMC) $222 Huadong Medicine Co Ltd. Gains Access to Sinclair Pharma’s Highly Differentiated Aesthetics Products to Expand Business Beyond China into United States and Other MarketsSinclair Pharma plcAcquisitionChina
WuXi NextCODE$200 WuXi NextCODE is focusing the proceeds from this round on rapidly expanding operations at GMI, and to accelerate the program to enroll and sequence the entire genome of some 400,000 people from across Ireland. Ireland Strategic Investment Fund (ISIF)Series C FinancingIreland
Strongbridge Biopharma plc $145 Novo Nordisk to acquire the rights to MACRILEN™ (macimorelin) in the United States (U.S.) and Canada. MACRILEN is the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency (AGHD).Novo NordiskDivestmentUnited States
Suzhou Hybiome Biomedical Engineering$130 Hybiome is specialized in automated immunoassay tests. Hybiome markets two automated, mid-throughput immunoassay systems (AE-180 and AE-240) using the latest generation CLIA1 technology and featuring a menu of nearly 80 parameters. Hybiome also recently received CFDA clearance for the AE-120 system, to further increase access to its menu of assays.bioMérieux54% StakeChina
Denali Therapeutics$125 The two lead molecules (DNL747 and DNL758) target a critical signaling protein known as the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. The companies plan to study DNL747 in multiple sclerosis (MS), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS), and DNL758 in systemic inflammatory diseases such as rheumatoid arthritis and psoriasis.SanofiCollaborationUnited States
Mirum Pharmaceuticals$120 Maralixibat Phase 2b study interim analysis suggests proof of concept in Alagille syndromeCombined leadership from former Lumena and Tobira teams to pursue registration in Alagille syndrome, progressive familial intrahepatic cholestasis and other liver diseasesNew Enterprise Associates, ShireSeries A FinancingUnited States
Alphamab Oncology$100 Alphamab Oncology plans to use the proceeds to advance global clinical development of its innovative pipeline, especially its second-generation immuno-oncology medicine, to expand its global clinical and commercial teams, as well as to complete the ongoing construction of its state-of-the-art biologics manufacturing facilities.Advantech CapitalSeries A FinancingChina
Immunocore Limited$100 Immunocore will lead the first-in-human clinical trial to establish safety and preliminary efficacy of IMC-C103C as both monotherapy and in combination with atezolizumab (Tecentriq®). The clinical trial, which is scheduled to commence in early 2019, will enrol patients across a number of solid tumour types.Genentech (Roche Group)PartnershipUnited Kingdom
Aimmune Therapeutics$98 Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101.Nestlé Health ScienceEquity InvestmentUnited States
NextCure$93 The proceeds will be primarily used to support clinical development for the company’s two lead drug candidates, including NC318, preclinical development of additional novel immunomedicine drug candidates, and the Company’s activities under its previously announced collaboration with Eli Lilly and Company to discover and develop novel cancer targets with the Company’s proprietary FIND-IO™ platform.Hillhouse Capital ManagementSeries B FinancingUnited States
Center for Protein Degradation at Dana-Farber$80 The goal of the Center for Protein Degradation is to interrogate and advance a large portfolio of advanced targeted protein degrader targets while creating a next-generation protein degrader platform.Deerfield ManagementCollaborationUnited States
Greenville Site$80 As part of the Greenville site expansion, packaging capacity has more than doubled. One bottling line is dedicated for clinical packaging, and two commercial bottling lines have been qualified for serialization.Metrics Contract Services (Mayne Pharma Group Limited)Manufacturing InvestmentUnited States
SIGA Technologies$80 SIGA was awarded the PRV in July 2018 upon approval by the U.S. Food and Drug Administration (FDA) of oral TPOXX® for the treatment of smallpox.Eli LillyPriority Review Voucher SaleUnited States
ViaCyte $80 ViaCyte currently has two stem cell-derived islet replacement therapy candidates at the clinical stage: PEC-Direct and PEC-Encap. The PEC-Direct product candidate is being developed as a transformative therapy for high-risk type 1 diabetes patients and is currently being evaluated in the second stage of a Phase 1/2 trial, with initial proof-of-efficacy data expected as early as mid-2019. TPGSeries D FinancingUnited States
Centrexion Therapeutics$75 CNTX is developing CNTX-4975 currently in Phase 3 trials, a drug designed to selectively and locally target and disrupt the signaling of pain-sensing nerve fibers in patients with moderate to severe pain due to knee OA.UndisclosedIPOUnited States
PellePharm$70 The agreement establishes a joint development committee with PellePharm maintaining responsibility for global development and LEO Pharma supporting in an advising role.LEO PharmaCollaborationUnited States
Harpoon Therapeutics$70 Harpoon’s TriTAC platform was designed to advance the therapeutic potential of T cell engagers, with a long half-life extended format. Harpoon is developing a pipeline of four wholly owned TriTAC product candidates. Harpoon’s lead product candidate, HPN424, is currently in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer, or mCRPC.Lilly Asia VenturesSeries C FinancingUnited States
Kymera Therapeutics$65 The financing will support the advancement of its lead asset into clinical development, and to progress its therapeutic pipeline in oncology and immunology. Kymera also entered into a two-year discovery collaboration agreement with GSK, leveraging innovations in small molecule-based targeted protein degradation and encoded library technologies.6 Dimensions CapitalSeries B FinancingUnited States
Aprea Therapeutics$57 Proceeds from the financing will be used to advance the clinical development of APR-246, a first-in-class anticancer agent that reactivates mutated p53 tumor suppressor protein. Aprea is planning to begin a Phase 3 clinical study in myelodysplastic syndromes (MDS) and is nearing completion of a Phase Ib/II clinical trial in p53 mutated high-risk myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML) with APR-246 and azacitidine.Redmile GroupSeries C financingUnited States
Yuhan Corporation$50 The collaboration's aim is to develop Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC).Janssen BiotechCollaborationSouth Korea
Prometic Life Sciences$50 With R&D costs expected to fall by $30 million in 2019, one side of the equation looks to be in place. However, Prometic is yet to land the deal it needs to deliver a hit of non-dilutive financing and secure the future of Ryplazim and its other pipeline prospect PBI-4050.Canaccord Genuity Corp.Private PlacementCanada
BioArctic AB$50 BAN0805 is the most advanced of the BioArctic alpha-synuclein antibodies, that are being developed as a disease modifying treatment of Parkinson's disease with a goal to potentially impact disease progression. Preparation of an IND-application is ongoing in order to start the first clinical study with BAN0805 in the US 2019.AbbVieOption ExerciseSweden
Dragonfly Therapeutics $50 The new agreement builds upon Celgene's existing four-target collaboration with Dragonfly, agreed upon in 2017, and increases the number of TriNKET™ immunotherapy drug candidates available for in licensing by Celgene to a total of eight.Celgene CorporationCollaborationUnited States
Inflazome$46 Inflazome is developing potent and selective small-molecule inhibitors of the NLRP3 inflammasome, to stop the cycle of chronic inflammation that drives such diseases. The Series B proceeds will be used to advance the Company’s first-in-class NLRP3 inflammasome inhibitors into multiple clinical trials in 2019, with next-generation compounds following thereafter.ForbionSeries B FinancingIreland
Camel-IDS$42 Camel-IDS is developing new radiopharmaceuticals based on linking single domain antibody fragments with radioisotopes to treat cancer. Funding will be used for a phase Ib/II trial of the lead program CAM-H2, while further developing preclinical programs and broadening the pipeline.HealthCapSeries A FinancingBelgium
Zymeworks$40 Zymeworks has granted BeiGene exclusive rights to develop and commercialize Zymeworks’ clinical-stage bispecific antibody candidate ZW25 and its preclinical-stage bispecific antibody drug conjugate (ADC) ZW49 in Asia (excluding Japan), Australia, and New Zealand.BeiGeneCollaborationCanada
RegenXBio$40 REGENXBIO grants Abeona new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten DiseaseAbeona Therapeutics Licensing AgreementUnited States
NextCure$40 The multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to discover novel cancer targets utilizing NextCure's proprietary FIND-IO™ platform.Eli LillyCollaborationUnited States
Cadent Therapeutics$40 Cadent Therapeutics is developing novel allosteric modulators of ion channels to improve neuronal firing regularity. This first-of-its-kind approach has the potential to restore neuronal control and benefit patients with movement and cognitive disorders.Cowen Healthcare InvestmentsSeries B FinancingUnited States
VISEN Pharmaceuticals$40 Ascendis has granted Visen exclusive rights to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP in Greater China, and has received 50 percent ownership of Visen.Vivo Capital, Ascendis Pharma A/SJoint VentureChina
AcelRx Pharmaceuticals$40 AcelRx intends to use the net proceeds from the offering, in addition to its existing cash resources, to fund the commercial launch of DSUVIA and for general corporate purposes.UndisclosedIPOUnited States
Cabaletta Bio$38 The Company’s lead product is designed to selectively eradicate B cells that produce autoantibodies to desmoglein 3 (DSG3), which are necessary to cause mPV. The engineered T cell technology utilizes chimeric autoantibody receptors (CAARs) to bind and destroy only disease-causing B cells, while sparing the normal B cells which are essential for human health.University of PennsylvaniaLicensing AgreementUnited States
Avenue Therapeutics$35 The novel intravenous drug delivery method of Tramadol addresses extremely crucial and hitherto unmet needs in pain management. This investment is in keeping with our stated intention to build a specialty pipeline in the U.S. market, and reinforces Cipla’s innovation-led approach and commitment to caring for the life of patients.InvaGen Pharmaceuticals (Cipla)33% StakeUnited States
Ribometrix$30 Ribometrix’s discovery pipeline focuses on targeting RNA molecules that fold into complex 3D structures yielding pockets amenable to small molecules with high selectivity and favorable drug-like characteristics.Amgen VenturesSeries A FinancingUnited States
F2G Biotech GmbH$27 F2G will be spending most of its resources on R&D, in particular on the clinical trials of its lead compound “Olorofim”.European Investment Bank (EIB)InvestmentAustria
Adrenomed AG$27 The new funds will be used to execute a proof-of-concept clinical program of lead product candidate Adrecizumab in early septic shock - Adrecizumab provides a highly novel approach to treat life-threatening conditions by focusing on the preservation of vascular integrity.Wellington PartnersInvestmentGermany
Antios Therapeutics$25 The proceeds from this financing will be used to develop ATI-2173, Antios' lead oral drug candidate for treating patients infected with Hepatitis B virus (HBV) and potentially Hepatitis D virus (HDV).Lumira VenturesSeries A FinancingUnited States
Rheostat Therapeutics$23 Proceeds will be used to advance its programs towards clinical trials, build its internal team and expand studies evaluating biomarkers.AbbVie VenturesSeries A FinancingUnited States
Santhera Pharmaceuticals$20 Initial clinical data suggest that vamorolone has the anti-inflammatory efficacy of steroids with reduced steroid-associated safety concerns, which would represent a significant improvement over current standard of care glucocorticoid therapy in patients with Duchenne muscular dystrophy (DMD), vamorolone's lead indication.IdorsiaOption AgreementSwitzerland
ADC & Biologics Drug Substance Manufacturing Facility$20 Abzena’s antibody Drug Substance manufacturing solution will be built in two new suites housed in the facility recently opened by Abzena in San Diego. These will contain new Sartorius 500 L and 2000 L single use bioreactors supported by a comprehensive range of scale up and process development equipment. The service will be further complemented by additional cell line development and chemistry capacity.AbzenaManufacturing InvestmentUnited States
OMEICOS Therapeutics GmbH$20 The proceeds from this round will finance PROMISE-AF, a placebo controlled, double-blinded, randomized, dose finding Phase II study on OMT-28 in maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation. ForbionSeries C FinancingGermany
OMass Therapeutics$18 The Oxford University spinout plans to use the investment to fuel its structural mass spectrometry to identify new medicines.SynconaSeries A FinancingUnited Kingdom
Epizyme$15 The global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer.Boehringer IngelheimCollaborationUnited States
Vectura Group plc$15 Vectura and Hikma believe the Open-Inhale-Close dry powder inhaler device has the potential to be developed as an AB-rated substitutable drug-device combination for generic versions of the GSK Ellipta® portfolio. Hikma and Vectura have agreed to develop and commercialise at least three of the portfolio products. Hikma Pharmaceuticals Commercialization AgreementUnited Kingdom
Advent Pharmaceuticals Pty Ltd.$13 Acquisition of certain R & D assets from Advent Pharmaceuticals pty Ltd., Australia, which is into the business of R & D in complex specialty generics. Acquisition provides an opportunity to acquire assets that would be used for specialty generics business.Aurobindo Pharma USAAsset AcquisitionAustralia
Vedanta Biosciences$12 The initiation of a Phase 1 clinical study of VE202, the Company’s orally-administered, live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD) that was licensed to Janssen Biotech, Inc. in 2015. Vedanta Biosciences will receive $12 million from Janssen in milestone payments as part of the ongoing collaboration. Vedanta Biosciences advanced VE202, a drug candidate consisting of a rationally-defined consortium of regulatory T cell – inducing bacteria.Janssen BiotechMilestone PaymentUnited States
BioTime$11 “AgeX was created by BioTime to develop a pipeline of aging and age-related disease programs and this strategic sale of half of our ownership to Juvenescence for $43 million while distributing most of the remaining shares to BioTime shareholders is an excellent example of our two-pronged approach of unlocking value from our platform while investing in our core programs."Juvenescence LimitedInstallment PaymentUnited States
Mapi Pharma Ltd.$10 Mapi Pharma is engaged in the development of high barrier-to-entry, high added-value lifecycle management pharmaceuticals and complex active pharmaceutical ingredients (“APIs”) and formulations. The funds raised will support Mapi’s future development and enable the expansion of the company’s pipeline to additional 505(b)(2) and Depot innovative and QQ products beyond the lead product, Glatiramer Acetate (Copaxone®) Depot, or GA Depot, for the treatment of multiple sclerosis (MS) which is in finaZhejiang Jingxin Pharmaceutical Co.InvestmentIsrael
Regulus Therapeutics Inc.$7 Regulus has granted Sanofi a worldwide exclusive license to develop and commercialize its investigational drug, targeting miR-21 for all indications, including Alport syndrome.SanofiLicensing AgreementUnited States
Intensity Therapeutics$7 Intensity plans to use the proceeds of the financing to advance the clinical development of lead product candidate INT230-6, a direct intratumoral injection that is currently being evaluated in a Phase 1/2 clinical study in patients with various advanced solid tumorsUndisclosedSeries B FinancingUnited States
Arc Trinova, Autolus Ltd$5 The £4.3 million funding aims to create more efficient and innovative methods for manufacturing medicines. The challenge works to set the UK apart as a leader with greater capacity for manufacture of safe, affordable and effective therapies.Innovate UKGovernment FundingUnited Kingdom
I-Mab Biopharma$4 MOR210 is MorphoSys's proprietary, preclinical-stage antibody directed against C5aR. I-Mab will exercise its exclusive license rights for development and commercialization of MOR210 in its territories. With support from MorphoSys, I-Mab will perform and fund all global development activities for MOR210, including clinical trials in China and the U.S., towards clinical proof-of-concept (PoC) in oncology.MorphoSys AGPartnershipChina
ADC Biotechnology$3 Charlie Johnson, CEO of ADC Bio commented: “We are delighted to have obtained this additional injection of funds that will be used to support the company’s strategic aspirations, including conceptual design of a downstream formulation and filling operation to complement our existing bioconjugation operations at the Deeside facility. We are also looking to fully exploit our core Lock-Release technology to create a transformative manufacturing paradigm that will significantly streamline ADC manufaMaven Capital PartnersManufacturing InvestmentUnited Kingdom
Aspect Biosystems$3 Aspect Biosystems is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine.Government of CanadaGovernment FundingCanada
Oxford BioMedica$3 OXB is committed to investing in the UK and has recently announced the expansion of its manufacturing capacity to create an additional 82,398 sqft facility near its headquarters in Oxford. This new facility secures Oxford as a bioprocessing centre for OXB and will create up to 100 new, highly skilled positions at the Group over the next two years.Innovate UKGovernment FundingUnited Kingdom
Clinical Supply Facility$3 The new 30,000 square-feet facility in Tangzhen, a district of Shanghai, will have three controlled temperature rooms operating at 2-8°C, 15-25°C, and -20°C, and will also offer returns and destruction services. Its location, outside of the Free Trade Zone (FTZ), will provide clinical trial sponsors with increased speed and efficiency when running trials in China, and its proximity to Catalent’s existing FTZ facility in Waigaoqiao, within China’s Zhangjiang Pharma Valley, will allow the company Catalent Pharma SolutionsManufacturing InvestmentChina
Synbal$2 The company will leverage their proprietary next-generation gene-editing platform, Active Genetics, to develop a preclinical model that expresses human drug metabolizing enzymes collectively termed P450.National Cancer InstituteGovernment FundingUnited States
EyePoint Pharmaceuticals$2 The License agreement is for the development and commercialization of EyePoint’s three-year micro insert using the Durasert™ technology for chronic, non-infectious posterior segment uveitis in the greater China territory, which is comprised of China, Hong Kong, Macau and Taiwan. Ocumension TherapeuticsLicensing AgreementUnited States
Recursion Pharmaceuticals$2 For the Phase 1 grant, Recursion set out to develop a morphological profile for senescent cells in a variety of human cell types, independent of existing biomarkers. For Phase 2, the company will leverage its platform to discover novel senolytic agents, molecules that preferentially destroy senescent cells while leaving healthy tissue intact.National Institutes of Health (NIH) Government FundingUnited States
Pola Pharma Inc.$1 The portfolio of Pola Pharma primarily comprises dermatology products. Pola Pharma is a leading dermatology company and it will help [Sun] to launch its speciality and generic dermatology products in the Japanese market in future. Sun Pharma "also gets access to local manufacturing capability enabling us to serve the Japanese pharmaceutical market more effectively.”Sun Pharmaceutical Industries Ltd.AcquisitionJapan
Olaregen Therapeutix$0.4 Olaregen’s pipeline will focus on developing Excellasome® for the regeneration of bones, joints and cartilage. R&D efforts will address the use of Excellasome® in the treatment Osteo and Rheumatoid Arthritis, cartilage repair and plantar fasciitis.Generex Biotechnology Corporation51% StakeUnited States
NeuroVive Pharmaceutical AB$0.2 The development program that Vinnova is supporting involves formal preclinical development, including toxicology studies and process development for large-scale manufacture of NV354.VinnovaInvestmentSweden
University of PennsylvaniaUndisclosedPenn will be responsible for a dedicated preclinical research program from discovery through to the completion of IND-enabling studies in up to ten infectious disease indications. The goal of the exclusive, multi-year partnership is to develop novel nucleoside-modified mRNA vaccine candidates for the prevention and treatment of various infectious diseases.BioNTech AGCollaborationUnited States
Infinity PharmaceuticalsUndisclosedInfinity will operationalize MARIO-275: MAcrophage Reprogramming in Immuno-Oncology, a global, randomized Phase 2 study to evaluate the effect of adding IPI-549 to Opdivo in checkpoint-naïve advanced urothelial cancer patients who have progressed or recurred following treatment with platinum-based chemotherapy.Bristol-Myers SquibbClinical CollaborationUnited States
Crescendo BiologicsUndisclosedTakeda has taken an exclusive licence to Humabodies directed to one of its oncology targets. This licence option exercise comes substantially earlier than planned and marks the highly successful delivery and further pre-clinical evaluation by Takeda of Humabody® leads meeting its stringent criteria.Takeda Pharmaceutical Company LimitedLicensing AgreementUnited Kingdom
Enesi PharmaUndisclosedThe collaboration is focused on the development and evaluation of solid dose versions of Sementis' lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma's ImplaVax® technology. Enesi Pharma will formulate solid dose implants based on SCV vaccine provided by Sementis, and Sementis will undertake safety and immunogenicity testing, and preclinical development. Pending positive outcomes, this agreement would set the foundaSementisCollaborationUnited Kingdom
BioContinuum™ Platform for Next Generation BioprocessingUndisclosedMerck launched its new BioContinuum™ Platform to advance biotherapeutic drug manufacturing through improved efficiency, simplified plant operations and greater quality and consistency. The Life Science business sector of Merck also introduced its expanded Pellicon® Single-Pass Tangential Flow Filtration system to intensify operations in the purification of therapeutic proteins.Merck KGaAManufacturing InvestmentGermany
Nano Creaciones S.A. P.I. de D.V. Research LLCUndisclosedThe Nano Gauze is made from pure silver nanoparticles, which are carefully dispersed in cotton fibers that are subjected to a meticulous sterilization process with the most advanced technology for contact with wounds and human tissues without compromising the action of the silver nanostructures. Apotheca Biosciences believes that using Nano’s products to deliver CBD as a palliative will bring the utmost quality and precise dosing to the consumer market.Apotheca BiosciencesLetter of IntentBrazil
PHOENIX groupUndisclosedThe companies will be working at strategic partnership level on commercial opportunities to provide better access to Zentiva products for the benefit of patients across Europe.ZentivaAllianceCzech Republic
G&W LaboratoriesUndisclosedG&W Dermatology has a market-leading and diversified portfolio of approximately 35 self-labeled generic topical dermatology products that are currently marketed and sold in the U.S.Avista Capital PartnersBusiness Unit AcquisitionUnited States
HuiyiHuiyingUndisclosedHY is collaborating with more than 800 medical institutions in China in clinical applications and scientific research projects, including the Chinese PLA General Hospital, Peking Union Medical College Hospital, Beijing Friendship Hospital and several medical associations. Intel CapitalInvestmentChina
Medlac Pharma Italy Co. Ltd.UndisclosedThe acquisition includes a high-quality injectable facility, adjacent vacant land, Medlac’s product portfolio of 23 injectable products, its pipeline and all employees. Medlac operates an injectables facility in Hanoi, Vietnam. Since it commenced operations in 2012, it has built a strong reputation as a high-quality manufacturer in the areas of anti-infectives and cardiovascular.Hikma Pharmaceuticals AcquisitionVietnam
IRX TherapeuticsUndisclosedBrooklyn's advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.Brooklyn ImmunoTherapeuticsAcquisitionUnited States
Asterias BiotherapeuticsUndisclosed“Our vision is to build BioTime into a premier cell therapy company and this acquisition can support that transformation as it not only diversifies our pipeline with two additional clinical-stage assets addressing high unmet medical needs, but also adds partnerships with notable institutions such as the California Institute for Regenerative Medicine and Cancer Research UK,” stated Brian M. Culley, Chief Executive Officer of BioTime.BioTimeMergerUnited States
Prenetics LimitedUndisclosedThe joint venture will work on a direct-to-consumer model, allowing consumers the ability to purchase its suite of genetics enabled health services directly online. The joint venture will also seek collaborations with insurers, governments and other key stakeholders to ensure local market needs are met. The services will launch in the first quarter of next year.Berry GenomicsJoint VentureChina
Cincinnati Children's Hospital Medical CenterUndisclosedThis partnership will combine BridgeBio's strengths in therapeutic development for diseases of high unmet need with Cincinnati Children's world-class researchers and clinicians toward the mutual goal of discovering new therapies targeting genetic diseases at the source.BridgeBio PharmaCollaborationUnited States
BioArctic ABUndisclosedBioArctic has obtained financial support for a postgraduate studentship linked to Uppsala University in Sweden to contribute to the education of young researchers. The company may get access to a technology that can lead to even better diagnostic tools and biomarkers as well as PET ligands for the protein alpha-synuclein. The research initiative contributes to the development of new treatments for Parkinson's disease.EU's Horizon 2020Government FundingSweden
Medicines Patent PoolUndisclosedThe licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in 99 low- and middle-income countries (LMICs) and territories at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens.AbbVieLicensing AgreementUnited States
Kadimastem, DefymedUndisclosedKadimastem is developing an innovative cell therapy for diabetes by producing functional cells capable of producing and releasing insulin according to blood sugar levels. Defymed has developed MailPan®, a Bio-Artificial Pancreas device designed, using suitable cells such as Kadimastem's cells, to treat diabetes in patients without the use of immunosuppressants.EUREKA's Eurostars ProgrammeGovernment FundingIsrael
Linde AGUndisclosedThe N-Tidal devices are unique breath monitors capable of unprecedentedly precise measurement of the tidal breathing CO2 waveform shape, which is an established but under-used respiratory biomarker. Cambridge Respiratory Innovations Limited (CRiL)CollaborationGermany
Liquidity ServicesUndisclosedThe partnership can provide immediate capital infusions by disposing of biopharma assets via online auctions, consignment sales or direct negotiations with global buyers. It also has the capital resources to purchase such assets outright in principal deals.Tiger Liquidity Services Biopharma PartnersPartnershipUnited States
INVO Bioscience Inc.UndisclosedThe INVOcell IVC device uses a woman’s own body as a natural incubator during fertilization and early embryo development.Ferring PharmaceuticalsCommercialization AgreementUnited States
GenomOncologyUndisclosedThe partnership between GO and IU is a part of Indiana University's Grand Challenge Precision Health Initiative (IUPHI) which is conducting clinical trials in triple negative breast cancer, multiple myeloma and pediatric sarcomas.Indiana University School of MedicinePartnershipUnited States
Rockford SiteUndisclosedPCI is pleased to announce the expansion of our Clinical site at Rockford, IL. Construction of the expanded Clinical Services facility began on November 12, 2018. The site is one of two US-based PCI locations supporting investigational medicinal products, complementing facilities in the UK, Europe and Australia.PCI Pharma ServicesExpansionUnited States
Averitas PharmaUndisclosedAveritas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics.GrünenthalAcquisitionUnited States
CellesceUndisclosedThe new partnership will expand the number of Repositive's partners on Cancer Models to 12. Repositive's integrated web-based solution, enables researchers to find cancer models derived from human tumours with many from commercial sources now searchable in one place.RepositivePartnershipUnited Kingdom
Kinetic DiscoveryUndisclosedThe acquisition builds up Exscientia's capabilities for tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology.ExscientiaAcquisitionUnited Kingdom
CLIA-Certified LabUndisclosedThe company’s 8,000-square-foot facility at 2252 Welsch Industrial Court in Maryland Heights is twice the size of its previous lab and provides a foundation for future growth.MogeneExpansionUnited States
KinderPharmUndisclosedPennsylvania-based KinderPharm is recognized for the only complete pediatrics clinical trial solution bolstered with advanced pharmacometric capabilities, including pharmacokinetic data analysis, PK/PD modeling, physiologically-based PK modeling, and population PK analysis, to facilitate efficient pediatric trial design and minimize patient numbers.SynteractAcquisitionUnited States
Mission TherapeuticsUndisclosedAlzheimer’s and Parkinson’s diseases are associated with the accumulation of misfolded, toxic proteins, which are believed to cause impaired function and death of nerve cells in the brain. DUBs play an important role in keeping a cell healthy by regulating the degradation of these proteins. AbbVie and Mission are aiming to develop potential therapeutics that enable the degradation of these toxic proteins and prevent their accumulation.AbbVie CollaborationUnited Kingdom
Sinopharm Nutraceuticals Industrial (Sinopharm Group)UndisclosedThe partnership is the exploration and execution of investment opportunities in the pharmaceutical, healthcare and biotechnology industries by leveraging each other's strengths and resources.Cedrus InvestmentsCooperation AgreementChina
Luxcel Biosciences, Little Island, Cork facility UndisclosedThe addition of Luxcel expands Agilent's cell analysis portfolio and brings new capabilities through technology and research which will drive advancements in this fast-evolving field for Agilent globally.Agilent Technologies IncExpansionIreland
Rentschler Aseptic Fill & Finish FacilityUndisclosedThe new facility of Rentschler Fill Solutions – fully equipped with the latest technical infrastructure – was completed in the record time of two years. Rentschler Fill Solutions expects approval from the US Food and Drug Administration (FDA) in 2019. Through the strategic partnership of Rentschler Fill Solutions, Rentschler Biopharma and Leukocare, clients also benefit from one-stop solutions from gene to vial and clinic to market.Rentschler Fill Solutions GmbHManufacturing InvestmentAustria
Pacific Biomarkers, NEOMED-LABSUndisclosedThis merger brings together two leading bioanalytical CROs with unrivaled credentials in immunology and particular expertise in assay development, custom biomarker validation, and high-throughput clinical sample testing.Ampersand Capital PartnersMergerUnited States
Enlivex Therapeutics Ltd.UndisclosedEnlivex is developing a novel immunotherapy with a unique mechanism of action that targets clinical indications that are defined as “life-threatening with an unmet medical need,” such as preventing or treating complications associated with bone-marrow transplantations and sepsis, (the third-leading cause of mortality in the U.S. after cardiovascular and cancer diseases) and as a treatment for solid tumors via immune checkpoint reprogramming, which could increase the efficacy of CAR-T, TCR and otBioblast Pharma Ltd.MergerIsrael
Syntropy (Palantir Technologies)UndisclosedSyntropy is expected to empower scientists and research centers with a collaborative technology platform to advance cancer research, help drive scientific discovery, and improve human lives. Syntropy aims to unlock the value of this untapped data, enabling the world's leading experts to collaborate in the fight against cancer and many other diseases.Merck KGaAJoint VentureUnited States
Ascletis BioScienceUndisclosedFollowing the first successful partnership and promising launch for Ganovo (Danoprevir), Ascletis and Roche have decided to embark on a Pegasys partnership. Roche will grant Ascletis an exclusive sales & marketing promotion right in Mainland China for Pegasys, a leading pegylated interferon treatment for Hepatitis B and C.RochePartnershipChina
Ennore API siteUndisclosedEnnore is a key API site in the PPS integrated site network, with capabilities from early development through commercial manufacturing, with an available capacity of over 300kL. The site supplies Key Starting Materials, Registered Starting Materials, Advanced Intermediates and APIs for both large pharma and biotech firms, in North America, Europe, and RoW markets.Piramal Pharma Solutions Manufacturing InvestmentIndia
Eurofins Genomics (Eurofins Scientific Group)UndisclosedEurofins Genomics and Synthego are ideal business partners given their unmatched flexibility for any kind of genomic research and applications of CRISPR. A combined understanding of their customers' challenges with CRISPR was the basis for the cooperation between the two life sciences leaders, and aligned interests and values in offering best in class solutions make the Eurofins-Synthego partnership all the more powerful.SynthegoPartnershipGermany
HitGenUndisclosedThis collaboration further emphasizes the role of HitGen in the rapidly developing field of DNA-encoded chemistry. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads which will be licensed exclusively to Biogen.BiogenCollaborationChina
Nutrino HealthUndisclosedThe companies recognized an opportunity to improve clinical outcomes for people with diabetes by integrating Nutrino's extensive food analysis infrastructure, nutrition science expertise and artificial intelligence (AI)-driven personalized insights with Medtronic's technology and future innovations.Medtronic plcAcquisitionUnited States
Ligand Pharmaceuticals IncorporatedUndisclosediMBP gains access to the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ in their drug discovery efforts. As part of the agreement, Ligand will fund and facilitate selected early antibody discovery activities and will in return receive an ownership position in iMBP. iMetabolic Biopharma CorporationPartnershipUnited States
Immuneering CorporationUndisclosedThe research collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery capabilities with Immuneering’s unique Artificial Intelligence-driven drug discovery platform to accelerate ligand identification for novel targets.Evotec AGCollaborationUnited States
Tessa TherapeuticsUndisclosedThe goal of the partnership is to scale Tessa’s therapies world-wide in a safe and efficient manner, supporting both late clinical stage therapies approaching commercialization and early-phase therapies progressing through various clinical stages. Tessa’s Virus-Specific T cell (VST) technology is showing compelling results and an excellent safety profile in the treatment of cancer.VinetiPartnershipSingapore
Dalton Pharma ServicesUndisclosedDalton will be responsible for the formulation and fill/finish of UM171, a constituent of ExCellThera`s lead technology, ECT-001, to support phase II clinical trials in Canada & the United States.ExCellThera Inc.Manufacturing PartnershipCanada
Biologics Innovation CenterUndisclosedThe new state-of-the-art biologics center will integrate biologics discovery, development, clinical and commercial manufacturing which will be built to meet global cGMP standards while implementing modular and flexible design. This will be one of the largest facilities of its kind with 1.6 million sq. ft. and will accommodate more than 3000 scientists.WuXi BiologicsManufacturing InvestmentChina
PHOENIXUndisclosedThe first projects to commence under the strategic partnership are being rolled out in certain Central & Eastern European (CEE) markets. "In PHOENIX we are confident that we have found the right partner for distribution and commercial activities. We are looking forward to expanding our collaboration to benefit even more markets in the future," says Robert Storch, Head of Trade & Revenue, Zentiva Group.ZentivaPartnershipGermany
Lucence DiagnosticsUndisclosediGenetic will be distributing Lucence’s flagship liquid biopsy test – LiquidHALLMARK - a blood test to span multiple cancer-causing mutations and viruses. The blood test analyzes the cancer-driving mutations from the DNA shed by the tumor into the bloodstream to determine the best available treatment, which include targeted therapy and immunotherapy.iGenetic DiagnosticsDistribution AgreementSingapore
Seracare Life SciencesUndisclosedThe acquisition of SeraCare strengthens LGC's position across the spectrum of clinical quality control tools market and builds upon its existing calibration verification materials and proficiency testing offerings including those of LGC Maine Standards, acquired in 2015.LGC GroupAcquisitionUnited Kingdom
Edge TherapeuticsUndisclosedPDS Biotechnology is developing PDS0101 for the treatment of multiple human papilloma virus (HPV)-induced cancers, including cervical, anal and head and neck cancers. PDS Biotechnology plans to initiate multiple Phase 2/3 clinical trials for PDS0101 in HPV-associated cancers.PDS Biotechnology CorporationMergerUnited States
Fusion AntibodiesUndisclosedThis collaboration will boost Fusion Antibodies’ continual efforts to improve its algorithms to understand the structure/function relationship of its target antibodies. Fusion Antibodies’ CDRx™ humanization platform makes it possible to perform multiple virtual experiments with panels of selected antibodies to discover properties that meet desired functionality and developability requirements with the long-term goal of reducing development costs and accelerating timelines so that novel antibody Analytics EnginesCollaborationNorthern Ireland
Jecure TherapeuticsUndisclosedGenentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors.Genentech (Roche Group)AcquisitionUnited States
Shefield & SonsUndisclosedAbattis' vaporizers provide therapeutic benefits in the delivery of cannabidiol and tetrahydrocannabinol extracts, utilizing a system of rapid absorption for the quick delivery of cannabinoids. With the Distribution Agreement in place, the Company is anticipating increased sales growth of its entire vaporizer line for 2019.Abattis Bioceuticals CorpDistribution AgreementCanada
University of Nottingham, BC PlatformsUndisclosedThe collaboration will see BC Platforms opening up its connector technology across the biobanking platform in order to develop an open standard that can be utilised and reimplemented by any accredited party. The biobanking platform - - is hosted by the University of Nottingham's UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) and run under the national registry for biobanks holding over 150 biobanks.UKCRC Tissue Directory and Coordination CentreCollaborationSwitzerland
Daiichi SankyoUndisclosedRoche will seek to develop, manufacture and commercialize worldwide an immunohistochemistry (IHC) companion diagnostic test with the goal of identifying patients with HER2 low expressing metastatic breast cancer to be enrolled into a pivotal phase 3 study evaluating the safety and efficacy of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC).RocheCollaborationJapan
Accinov GMP manufacturing siteUndisclosedThe new Lyon site will focus on providing ABL’s clients with increased options and capacities in response to the rapid growth in demand for the production of viral vectors observed in the immuno-oncolytic and gene therapy space.Advanced BioScience Laboratories (ABL)AcquisitionFrance
Generex Biotechnology CorporationUndisclosedThe clinical trial, sponsored by Generex and conducted in conjunction with Merck, is currently being reviewed by the FDA, and clinical operations including site qualification, drug shipment and packaging, and IRB review and approval are underway, with plans to enroll patients in the first quarter of 2019.NSABP FoundationClinical CollaborationUnited States
X4 PharmaceuticalsUndisclosedThe merger would result in a combined company operating under the X4 Pharmaceuticals name that will focus on the development and commercialization of X4’s lead product candidate, X4P-001, and the advancement of X4’s pipeline of treatments for rare diseases of the immune system and rare cancers.ArsanisMergerUnited States
Aileron TherapeuticsUndisclosedALRN-6924 is a first-in-class, stabilized cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt the interaction with both its endogenous inhibitors, MDMX and MDM2. Palbociclib is an oral inhibitor of cell cycle check-point regulators CDK4/6. Aileron expects this Phase 1B trial to start enrolling patients with solid tumors in the first quarter of 2019. Pfizer will provide drug supply in support of the trial.PfizerClinical CollaborationUnited States
Stevenage Bioscience Catalyst (SBC) Open Innovation CampusUndisclosedIn the first half of 2019, the center will start producing a fiber-based purification platform, which has the potential to significantly improve efficiency in the purification steps of manufacturing biopharmaceuticals, gene therapies and viral vectors. “The fiber-based chromatography technology developed and manufactured in Stevenage will extend GE Healthcare’s start-to-finish bioprocess purification portfolio.”GE Healthcare Life SciencesManufacturing InvestmentUnited Kingdom
Elto Pharma Subs Amarantus Biosciences HoldingsUndisclosedElto Phama is developing eltoprazine, a serotonergic agonist in Phase 2b development for the treatment of Parkinson's disease levodopa-induced dyskinesias (Parkinson's LID).Coeptis PharmaceuticalsAcquisitionUnited States
ABL Bio CorporationUndisclosedThe agreement showcases the expansive biologics pipeline of ABL Bio and the world leading technical expertise and capabilities of WuXi Biologics in developing bispecific programs.WuXi Biologics has enabled several preclinical and clinical manufacturing programs for ABL Bio as well as collaboration with I-Mab," said Dr. Sang Hoon Lee, Chief Executive Officer of ABL Bio.WuXi Biologics Manufacturing PartnershipSouth Korea
Neuro Motor Innovations Corporation (NMI)UndisclosedMindMaze will further develop and commercialize NMI's technology that targets treatment of a wide range of neurological diseases and injuries from the acute through chronic stages. Additionally, the immersive cognitive-motor experiences can be used for healthy aging and wellness, as it has become apparent that complex movements are essential for maintaining executive cognitive function.MindMazeAcquisitionUnited States
GE HealthcareUndisclosedThe agreement gives Q BioMed ownership of the brand, trademarks and market authorizations in 22 countries.Q BioMed IncProduct AcquisitionUnited States
Wellthy TherapeuticsUndisclosedRoche announced its partnership with the digital therapeutic company Wellthy Therapeutics to offer users of the Accu-Chek Active system, a clinically validated artificial intelligence-based digital diabetes coaching solution. The bundle is being launched in the South and West Zones of India.Roche Diabetes Care IndiaPartnershipIndia
I-Mab BiopharmaUndisclosedTRACON and I-Mab entered into a cost-sharing product development collaboration whereby TRACON will be responsible for the regulatory and clinical development of TJD5 and up to five of the BsAbs in North America, with the majority of the development effort expected to occur in the U.S.TRACON PharmaceuticalsPartnershipChina
Jianke, the first B2C Internet drug company to be approved and be in full compliance with all medical requirements for operation in Guangdong province. announced the new brand image for Jianke Doctor to the public for the first time, and entered into a strategic collaboration with Pfizer.Pfizer ChinaCollaborationChina
Autolus Therapeutics plcUndisclosedAbCellera is applying its microfluidic single-cell screening platform to find novel antibodies which can be used for the development of new Chimeric Antigen Receptor (CAR) T cell therapies.AbCellera Biologics Inc.CollaborationUnited Kingdom
Hutchison MediPharma LimitedUndisclosedInnovent and Hutchison MediPharma will jointly explore potential application of this combination in solid tumors with global unmet medical needs through development efforts both in the US and in China.Innovent BiologicsClinical CollaborationChina
Bioquell PLCUndisclosedBioquell’s innovative bio-decontamination and isolator technologies and services help ensure residue-free surface decontamination in cleanrooms and research and development labs at biotech start-ups, pharmaceutical manufacturers and Fortune 500 companies, and in patient rooms at hospitals in more than 50 countries.Ecolab Inc.AcquisitionUnited Kingdom
GlaxoSmithKline UndisclosedCrown Laboratories has acquired North American distribution rights of five (5) OTC consumer brands from GlaxoSmithKlineCrown LaboratoriesDistribution AgreementUnited Kingdom
Pfizer Inc.UndisclosedAbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer’s proposed adalimumab biosimilar for many countries around the world. Pfizer may launch its adalimumab biosimilar upon approval by the European Medicines Agency in Europe. In the United States, the license period will begin on November 20, 2023.AbbVieIPR AgreementUnited States